Recent Finacing
Recent Raise
Cadenza Bio develops selective estrogen receptor‑β small‑molecule therapeutics to promote remyelination in multiple sclerosis, operating from an exclusive university license and partnerships launched in 2022.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Cadenza Bio.
